Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 392

1.

Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis.

Ota Y, Kuwana M.

Eur J Rheumatol. 2019 Dec 19:1-8. doi: 10.5152/eurjrheum.2019.19158. [Epub ahead of print] Review.

PMID:
31922471
2.

2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases.

Tanaka Y, Kuwana M, Fujii T, Kameda H, Muro Y, Fujio K, Itoh Y, Yasuoka H, Fukaya S, Ashihara K, Hirano D, Ohmura K, Tabuchi Y, Hasegawa H, Matsumiya R, Shirai Y, Ogura T, Tsuchida Y, Ogawa-Momohara M, Narazaki H, Inoue Y, Miyagawa I, Nakano K, Hirata S, Mori M.

Mod Rheumatol. 2020 Jan 7:1-5. doi: 10.1080/14397595.2019.1709944. [Epub ahead of print]

PMID:
31903831
3.

Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision.

Kashiwagi H, Kuwana M, Hato T, Takafuta T, Fujimura K, Kurata Y, Murata M, Tomiyama Y; Committee for the Revision of “Reference Guide for Management of adult ITP” Blood Coagulation Abnormalities Research Team, Research on Rare and Intractable Disease supported by Health, Labour and Welfare Science Research Grants.

Int J Hematol. 2020 Mar;111(3):329-351. doi: 10.1007/s12185-019-02790-z. Epub 2020 Jan 2. No abstract available.

PMID:
31897887
4.

Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.

Gono T, Kuwana M.

Expert Rev Clin Immunol. 2020 Jan;16(1):79-89. doi: 10.1080/1744666X.2019.1699059. Epub 2019 Dec 8.

PMID:
31779485
5.

Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.

Kuwana M, Azuma A.

Mod Rheumatol. 2019 Dec 20:1-7. doi: 10.1080/14397595.2019.1696505. [Epub ahead of print] Erratum in: Mod Rheumatol. 2019 Dec 20;:1.

PMID:
31747840
6.

Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis.

Watanabe E, Gono T, Kuwana M, Terai C.

Rheumatology (Oxford). 2019 Aug 13. pii: kez328. doi: 10.1093/rheumatology/kez328. [Epub ahead of print]

PMID:
31410476
7.

Clinical characteristics of cancer-associated myositis complicated by interstitial lung disease: a large-scale multicentre cohort study.

Kaneko Y, Nunokawa T, Taniguchi Y, Yamaguchi Y, Gono T, Masui K, Kawakami A, Kawaguchi Y, Sato S, Kuwana M; JAMI investigators .

Rheumatology (Oxford). 2020 Jan 1;59(1):112-119. doi: 10.1093/rheumatology/kez238.

PMID:
31382295
8.

Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with Sjögren's syndrome: Case series.

Ogawa A, Ogawa Y, Mukai S, Shimizu E, Kuwana M, Kawakami Y, Tsubota K.

Medicine (Baltimore). 2019 Jul;98(29):e16390. doi: 10.1097/MD.0000000000016390.

9.

Performance evaluation of a line blot assay system for detection of anti-PM-Scl antibody in Japanese patients with systemic sclerosis.

Hamaguchi Y, Kuwana M, Takehara K.

Int J Rheum Dis. 2019 Sep;22(9):1746-1751. doi: 10.1111/1756-185X.13638. Epub 2019 Jun 27.

PMID:
31245910
10.

Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.

Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.

Arthritis Rheumatol. 2019 Dec;71(12):2059-2067. doi: 10.1002/art.41020. Epub 2019 Nov 1.

PMID:
31233287
11.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators.

N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.

12.

The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method.

Yajima N, Tsujimoto Y, Fukuma S, Sada KE, Shimizu S, Niihata K, Takahashi R, Asano Y, Azuma T, Kameda H, Kuwana M, Kohsaka H, Sugiura-Ogasawara M, Suzuki K, Takeuchi T, Tanaka Y, Tamura N, Matsui T, Mimori T, Fukuhara S, Atsumi T.

Mod Rheumatol. 2019 Jun 26:1-7. doi: 10.1080/14397595.2019.1621419. [Epub ahead of print]

PMID:
31111758
13.

Two cases with autoantibodies to small ubiquitin-like modifier activating enzyme: A potential unique subset of dermatomyositis-associated interstitial lung disease.

Gono T, Tanino Y, Nishikawa A, Kawamata T, Hirai K, Okazaki Y, Shibata Y, Kuwana M.

Int J Rheum Dis. 2019 Aug;22(8):1582-1586. doi: 10.1111/1756-185X.13593. Epub 2019 May 2.

PMID:
31050194
14.

Rapid progression to end-stage renal disease in a young female with mixed immunopathological features of lupus and ANCA-associated vasculitis.

Fukue R, Takeno M, Miyamoto D, Shirai Y, Nagahama K, Shimizu A, Kuwana M.

Int J Rheum Dis. 2019 May;22(5):956-958. doi: 10.1111/1756-185X.13573. Epub 2019 Apr 9. No abstract available.

PMID:
30968562
15.

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.

Elhai M, Boubaya M, Distler O, Smith V, Matucci-Cerinic M, Alegre Sancho JJ, Truchetet ME, Braun-Moscovici Y, Iannone F, Novikov PI, Lescoat A, Siegert E, Castellví I, Airó P, Vettori S, De Langhe E, Hachulla E, Erler A, Ananieva L, Krusche M, López-Longo FJ, Distler JHW, Hunzelmann N, Hoffmann-Vold AM, Riccieri V, Hsu VM, Pozzi MR, Ancuta C, Rosato E, Mihai C, Kuwana M, Saketkoo LA, Chizzolini C, Hesselstrand R, Ullman S, Yavuz S, Rednic S, Caimmi C, Bloch-Queyrat C, Allanore Y; for EUSTAR network.

Ann Rheum Dis. 2019 Jul;78(7):979-987. doi: 10.1136/annrheumdis-2018-214816. Epub 2019 Apr 9.

PMID:
30967395
16.

Cyclophosphamide: similarities and differences in the treatment of SSc and SLE.

Bruni C, Shirai Y, Kuwana M, Matucci-Cerinic M.

Lupus. 2019 Apr;28(5):571-574. doi: 10.1177/0961203319840433. Epub 2019 Apr 8. Review. No abstract available.

PMID:
30961417
17.

Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017).

Fukuda K, Date H, Doi S, Fukumoto Y, Fukushima N, Hatano M, Ito H, Kuwana M, Matsubara H, Momomura SI, Nishimura M, Ogino H, Satoh T, Shimokawa H, Yamauchi-Takihara K, Tatsumi K, Ishibashi-Ueda H, Yamada N, Yoshida S, Abe K, Ogawa A, Ogo T, Kasai T, Kataoka M, Kawakami T, Kogaki S, Nakamura M, Nakayama T, Nishizaki M, Sugimura K, Tanabe N, Tsujino I, Yao A, Akasaka T, Ando M, Kimura T, Kuriyama T, Nakanishi N, Nakanishi T, Tsutsui H; Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group.

Circ J. 2019 Mar 25;83(4):842-945. doi: 10.1253/circj.CJ-66-0158. Epub 2019 Mar 9. No abstract available.

18.

Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review.

Kadota H, Gono T, Shirai Y, Okazaki Y, Takeno M, Kuwana M.

Curr Rheumatol Rep. 2019 Feb 21;21(4):10. doi: 10.1007/s11926-019-0811-3. Review.

PMID:
30790071
19.

Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations.

Aoyama J, Hayashi H, Yajima C, Takoi H, Tanaka T, Kashiwada T, Kokuho N, Terasaki Y, Nishikawa A, Gono T, Kuwana M, Saito Y, Abe S, Seike M, Gemma A.

Respir Med Case Rep. 2019 Jan 14;26:193-196. doi: 10.1016/j.rmcr.2019.01.012. eCollection 2019.

20.

Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.

Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, Fretheim H, Garen T, Kuwana M, Molberg Ø, Allanore Y.

Arthritis Rheumatol. 2019 Jun;71(6):972-982. doi: 10.1002/art.40815. Epub 2019 Apr 26.

PMID:
30624031
21.

β2-Glycoprotein I-Reactive T Cells in Autoimmune Disease.

Rauch J, Salem D, Subang R, Kuwana M, Levine JS.

Front Immunol. 2018 Dec 10;9:2836. doi: 10.3389/fimmu.2018.02836. eCollection 2018. Review.

22.

A case of cancer-associated myositis with anti-Mi-2 antibody: False-positive anti-transcriptional intermediary factor 1-γ antibody by commercial enzyme-linked immunosorbent assay.

Nawata T, Kubo M, Oishi K, Murata Y, Oishi M, Okazaki Y, Omoto M, Okazaki Y, Kanda T, Kuwana M, Yano M.

Int J Rheum Dis. 2019 Jul;22(7):1335-1339. doi: 10.1111/1756-185X.13449. Epub 2018 Dec 26. No abstract available.

PMID:
30588776
23.

Rapidly Progressive Multiple Digital Gangrene and Diffuse Alveolar Damage in a Patient With Antisynthetase Antibody and Gastric Cancer.

Fukue R, Gono T, Hayashi H, Terasaki Y, Kuwana M.

J Clin Rheumatol. 2018 Dec 21. doi: 10.1097/RHU.0000000000000974. [Epub ahead of print] No abstract available.

PMID:
30585991
24.

Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis.

Terao C, Yoshifuji H, Matsumura T, Naruse TK, Ishii T, Nakaoka Y, Kirino Y, Matsuo K, Origuchi T, Shimizu M, Maejima Y, Amiya E, Tamura N, Kawaguchi T, Takahashi M, Setoh K, Ohmura K, Watanabe R, Horita T, Atsumi T, Matsukura M, Miyata T, Kochi Y, Suda T, Tanemoto K, Meguro A, Okada Y, Ogimoto A, Yamamoto M, Takahashi H, Nakayamada S, Saito K, Kuwana M, Mizuki N, Tabara Y, Ueda A, Komuro I, Kimura A, Isobe M, Mimori T, Matsuda F.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):13045-13050. doi: 10.1073/pnas.1808850115. Epub 2018 Nov 29.

25.

Alterations in emotional responses (pleasantness/unpleasantness) induced by sniffing food odors during chemotherapy in patients with lung cancer.

Ishinaga K, Higa M, Yasuda M, Kuwana M, Nishiwaki C, Sunaga M, Okamura H.

Jpn J Clin Oncol. 2018 Oct 1;48(10):906-912. doi: 10.1093/jjco/hyy123.

PMID:
30165382
26.

Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.

Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, Hoshino T.

Respir Investig. 2018 Nov;56(6):464-472. doi: 10.1016/j.resinv.2018.07.007. Epub 2018 Aug 24.

PMID:
30150008
27.

KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.

Salazar GA, Kuwana M, Wu M, Estrada-Y-Martin RM, Ying J, Charles J, Mayes MD, Assassi S.

J Rheumatol. 2018 Aug;45(8):1153-1158. doi: 10.3899/jrheum.170518. Epub 2018 Jul 1.

PMID:
29961690
28.

Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: A case report.

Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, Kawakami A.

Medicine (Baltimore). 2018 Jun;97(26):e11024. doi: 10.1097/MD.0000000000011024.

29.

Diagnostic criteria, severity classification and guidelines of systemic sclerosis.

Asano Y, Jinnin M, Kawaguchi Y, Kuwana M, Goto D, Sato S, Takehara K, Hatano M, Fujimoto M, Mugii N, Ihn H.

J Dermatol. 2018 Jun;45(6):633-691. doi: 10.1111/1346-8138.14162. Epub 2018 Apr 23.

PMID:
29687465
30.

Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.

Kawasumi H, Katsumata Y, Nishino A, Hirahara S, Kawaguchi Y, Kuwana M, Yamanaka H.

J Rheumatol. 2018 Jul;45(7):947-955. doi: 10.3899/jrheum.170997. Epub 2018 Apr 15.

PMID:
29657141
31.

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report.

Endo Y, Koga T, Suzuki T, Hara K, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Kawakami A.

Medicine (Baltimore). 2018 Apr;97(15):e0436. doi: 10.1097/MD.0000000000010436.

32.

Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.

Mimori T, Harigai M, Atsumi T, Fujii T, Kuwana M, Matsuno H, Momohara S, Takei S, Tamura N, Takasaki Y, Yamamoto K, Ikeuchi S, Kushimoto S, Koike T.

Mod Rheumatol. 2019 Mar;29(2):314-323. doi: 10.1080/14397595.2018.1460230. Epub 2018 Apr 27.

PMID:
29611761
33.

Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients.

Sato S, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Tamura M, Ikeda K, Nunokawa T, Tanino Y, Asakawa K, Kaneko Y, Gono T, Ukichi T, Kaieda S, Naniwa T, Kuwana M; JAMI investigators .

Rheumatology (Oxford). 2018 Jul 1;57(7):1212-1221. doi: 10.1093/rheumatology/key060.

PMID:
29596687
34.

T cells from induced and spontaneous models of SLE recognize a common T cell epitope on β2-glycoprotein I.

Salem D, Subang R, Kuwana M, Levine JS, Rauch J.

Cell Mol Immunol. 2019 Aug;16(8):685-693. doi: 10.1038/s41423-018-0013-3. Epub 2018 Mar 23.

PMID:
29572548
35.

Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.

Ueki M, Kobayashi I, Takezaki S, Tozawa Y, Okura Y, Yamada M, Kuwana M, Ariga T.

Mod Rheumatol. 2019 Mar;29(2):351-356. doi: 10.1080/14397595.2018.1452353. Epub 2018 Apr 9.

PMID:
29532710
36.

Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody.

Gono T, Okazaki Y, Murakami A, Kuwana M.

Mod Rheumatol. 2019 Jan;29(1):140-145. doi: 10.1080/14397595.2018.1452179. Epub 2018 Apr 9.

PMID:
29529898
37.

Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy.

Shima Y, Kawaguchi Y, Kuwana M.

Mod Rheumatol. 2019 Jan;29(1):134-139. doi: 10.1080/14397595.2018.1452178. Epub 2018 Apr 9.

PMID:
29529897
38.

T-cell assays confirm immunogenicity of tungsten-induced erythropoietin aggregates associated with pure red cell aplasia.

Rubic-Schneider T, Kuwana M, Christen B, Aßenmacher M, Hainzl O, Zimmermann F, Fischer R, Koppenburg V, Chibout SD, Wright TM, Seidl A, Kammüller M.

Blood Adv. 2017 Feb 9;1(6):367-379. doi: 10.1182/bloodadvances.2016001842. eCollection 2017 Feb 14.

39.

Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC).

Oku K, Atsumi T, Akiyama Y, Amano H, Azuma N, Bohgaki T, Asanuma YF, Horita T, Hosoya T, Ichinose K, Kato M, Katsumata Y, Kawaguchi Y, Kawakami A, Koga T, Kohsaka H, Kondo Y, Kubo K, Kuwana M, Mimori A, Mimori T, Mimura T, Murakami K, Nakano K, Nakayamada S, Ogishima H, Ohmura K, Saito K, Sano H, Shibuya M, Takahashi Y, Takasaki Y, Takeuchi T, Tamura N, Tanaka Y, Tsuboi H, Tsunoda S, Yukawa N, Yamakawa N, Yamamoto K, Sumida T.

Mod Rheumatol. 2018 Jul;28(4):642-648. doi: 10.1080/14397595.2017.1385154. Epub 2017 Nov 9.

PMID:
29120258
40.

Predictors of Favorable Responses to Immunosuppressive Treatment in Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.

Yasuoka H, Shirai Y, Tamura Y, Takeuchi T, Kuwana M.

Circ J. 2018 Jan 25;82(2):546-554. doi: 10.1253/circj.CJ-17-0351. Epub 2017 Sep 12.

41.

Effectiveness and Outcome of Pulmonary Arterial Hypertension-Specific Therapy in Japanese Patients With Pulmonary Arterial Hypertension.

Tamura Y, Kumamaru H, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A, Abe K, Tsujino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K; Japan PH Registry (JAPHR) Network.

Circ J. 2017 Dec 25;82(1):275-282. doi: 10.1253/circj.CJ-17-0139. Epub 2017 Jul 26.

42.

HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis.

Chen Z, Wang Y, Kuwana M, Xu X, Hu W, Feng X, Wang H, Kimura A, Sun L.

J Rheumatol. 2017 Sep;44(9):1389-1393. doi: 10.3899/jrheum.170165. Epub 2017 Jul 15.

PMID:
28711882
43.

Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Khanna D, Furst DE, Clements PJ, Allanore Y, Baron M, Czirjak L, Distler O, Foeldvari I, Kuwana M, Matucci-Cerinic M, Mayes M, Medsger T Jr, Merkel PA, Pope JE, Seibold JR, Steen V, Stevens W, Denton CP.

J Scleroderma Relat Disord. 2017 Jan-Apr;2(1):11-18. doi: 10.5301/jsrd.5000231.

44.

RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase I Antibody-Positive Systemic Sclerosis.

Oka A, Asano Y, Hasegawa M, Fujimoto M, Ishikawa O, Kuwana M, Kawaguchi Y, Yamamoto T, Takahashi H, Goto D, Endo H, Jinnin M, Mano S, Hosomichi K, Mabuchi T, Ueda MT, Nakagawa S, Beck S, Bahram S, Takehara K, Sato S, Ihn H.

J Invest Dermatol. 2017 Sep;137(9):1878-1886. doi: 10.1016/j.jid.2017.04.028. Epub 2017 May 12.

45.

Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting.

Kuwana M.

J Nippon Med Sch. 2017;84(2):56-63. doi: 10.1272/jnms.84.56. Review.

46.

A To-Do List at Diagnosis of Systemic Sclerosis with Positive Anti-RNA Polymerase III Antibodies.

Kuwana M.

J Rheumatol. 2017 May;44(5):550-552. doi: 10.3899/jrheum.170037. No abstract available.

PMID:
28461517
47.

Pre-treatment interleukin-6 levels strongly affect bone erosion progression and repair detected by magnetic resonance imaging in rheumatoid arthritis patients.

Kondo Y, Kaneko Y, Sugiura H, Matsumoto S, Nishina N, Kuwana M, Jinzaki M, Takeuchi T.

Rheumatology (Oxford). 2017 Jul 1;56(7):1089-1094. doi: 10.1093/rheumatology/kex046.

PMID:
28340008
48.

Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis.

Terao C, Kawaguchi T, Dieude P, Varga J, Kuwana M, Hudson M, Kawaguchi Y, Matucci-Cerinic M, Ohmura K, Riemekasten G, Kawasaki A, Airo P, Horita T, Oka A, Hachulla E, Yoshifuji H, Caramaschi P, Hunzelmann N, Baron M, Atsumi T, Hassoun P, Torii T, Takahashi M, Tabara Y, Shimizu M, Tochimoto A, Ayuzawa N, Yanagida H, Furukawa H, Tohma S, Hasegawa M, Fujimoto M, Ishikawa O, Yamamoto T, Goto D, Asano Y, Jinnin M, Endo H, Takahashi H, Takehara K, Sato S, Ihn H, Raychaudhuri S, Liao K, Gregersen P, Tsuchiya N, Riccieri V, Melchers I, Valentini G, Cauvet A, Martinez M, Mimori T, Matsuda F, Allanore Y.

Ann Rheum Dis. 2017 Jun;76(6):1150-1158. doi: 10.1136/annrheumdis-2016-210645. Epub 2017 Mar 17. Review.

49.

Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis.

Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R.

J Rheumatol. 2017 Mar;44(3):319-325. doi: 10.3899/jrheum.160682. Epub 2017 Jan 15.

PMID:
28089977
50.

Sarcoplasmic MxA expression: A valuable marker of dermatomyositis.

Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y, Suzuki S, Suzuki N, Nishino I.

Neurology. 2017 Jan 31;88(5):493-500. doi: 10.1212/WNL.0000000000003568. Epub 2016 Dec 30.

PMID:
28039312

Supplemental Content

Loading ...
Support Center